Invokana Dosage

Generic name: CANAGLIFLOZIN 100mg
Dosage form: tablet, film coated
Drug class: SGLT-2 inhibitors

Medically reviewed by Drugs.com. Last updated on Mar 20, 2025.

Prior to Initiation of INVOKANA

Assess renal function before initiating INVOKANA and as clinically indicated .

In patients with volume depletion, correct this condition before initiating INVOKANA .

Recommended Dosage and Administration

Recommended Dosage for Glycemic Control in Adults and Pediatric Patients Aged 10 Years and Older

The recommended starting dosage of INVOKANA is 100 mg orally once daily to improve glycemic control, taken before the first meal of the day.
For additional glycemic control, the dosage of INVOKANA may be increased to the maximum recommended dosage of 300 mg once daily.

Recommended Dosage for Other Indications in Adults

The recommended dosage of INVOKANA is 100 mg orally once daily for the following indications in adults:

to reduce the risk of major adverse cardiovascular events (cardiovascular death, nonfatal myocardial infarction and nonfatal stroke) in adults with type 2 diabetes mellitus and established cardiovascular disease (CVD).
to reduce the risk of end-stage kidney disease (ESKD), doubling of serum creatinine, cardiovascular (CV) death, and hospitalization for heart failure in adults with type 2 diabetes mellitus and diabetic nephropathy with albuminuria greater than 300 mg/day.

Recommended Dosage in Adults and Pediatric Patients Aged 10 Years and Older with Renal Impairment

Table 1 provides dosage recommendations for adults and pediatric patients aged 10 years and older with renal impairment, based on estimated glomerular filtration rate (eGFR).

Table 1: Recommended Dosage in Adults and Pediatric Patients Aged 10 Years and Older with Renal Impairment
Estimated Glomerular Filtration Rate [eGFR (mL/min/1.73 m 2)]	Recommended Dosage
eGFR 30 to less than 60	The maximum recommended dosage is 100 mg orally once daily.
eGFR less than 30	Initiation is not recommended Adult patients taking INVOKANA with albuminuria greater than 300 mg/day may continue INVOKANA 100 mg once daily to reduce the risk of ESKD, doubling of serum creatinine, CV death, and hospitalization for heart failure.

Concomitant Use with UDP-Glucuronosyl transferase (UGT) Enzyme Inducers

When co-administering INVOKANA with an inducer of UGT (e.g., rifampin, phenytoin, phenobarbital, ritonavir), increase the dosage of INVOKANA based on renal function:

In patients with eGFR 60 mL/min/1.73 m 2or greater, increase the dosage to 200 mg orally once daily in patients currently tolerating INVOKANA 100 mg once daily. The maximum recommended dosage of INVOKANA is 300 mg once daily.
In patients with eGFR less than 60 mL/min/1.73 m 2, increase to a maximum recommended dosage of 200 mg orally once daily in patients currently tolerating INVOKANA 100 mg once daily.

Temporary Interruption for Surgery

Withhold INVOKANA at least 3 days, if possible, prior to surgery or procedures associated with prolonged fasting. Resume INVOKANA when the patient is clinically stable and has resumed oral intake.